Plus Therapeutics reimbursement push gains traction as AMA grants CNSide a dedicated PLA code
Plus Therapeutics has won an AMA PLA code for CNSide. Read why this reimbursement milestone could shape adoption, coverage, and diagnostic growth.
Medical Devices & Diagnostics
How REYOBIQ’s latest regulatory milestone may reshape the pediatric neuro-oncology landscape
Plus Therapeutics secures orphan designation for REYOBIQ in pediatric malignant gliomas. Read what this means for trials, exclusivity, and market strategy.